达比加群酯儿童VTE年龄体重剂量方案的药代动力学建模与模拟支持
该研究基于5项儿童VTE研究和1项健康成人研究建立达比加群群体PK模型,评估年龄和体重剂量算法。最终模型显示年龄、体重、BSA归一化肾功能和性别为显著协变量,模拟证实所有制剂剂量算法均达到参考暴露且无需调整。
要点
- 年龄、体重、BSA归一化肾功能和性别显著影响达比加群PK。
- 表观清除率随年龄增加、随BSA归一化肾功能降低而下降,女性低于男性。
- 模拟证实儿童剂量算法对所有达比加群酯制剂达到参考暴露,无需滴定。
核心结论
- 基于儿童VTE群体PK模型的模拟显示,最终年龄体重剂量算法适用于所有达比加群酯制剂,无需剂量滴定。
研究设计与样本
- 群体PK模型拟合4项单臂和1项随机对照儿童VTE研究(358例,出生至<18岁,2748个PK观测)及1项健康成人研究(32例男性,<40岁,1523个PK观测),采用非线性混合效应建模。
主要发现
- 达比加群群体PK由二室模型充分描述,一级消除和吸收。
- 年龄、体重、BSA归一化肾功能和性别为统计学显著协变量(所有P < .05)。
- 表观清除率随年龄增加(独立于体重),随BSA归一化肾功能降低而下降,女性低于男性。
- 所有处置参数随体重增加而增加(异速生长标度)。
- 模拟证实所有达比加群酯制剂最终儿童剂量算法达到参考暴露,无需剂量调整。
关键数值与推荐
- 年龄、体重、BSA归一化肾功能和性别为显著协变量(所有P < .05)。
- 模拟比较儿童谷浓度暴露与儿童研究定义的参考暴露,证实所有制剂剂量算法达到参考暴露。
临床怎么用
- 儿童VTE患者可按年龄和体重给予达比加群酯,所有制剂(口服溶液、颗粒、胶囊)均适用,无需剂量滴定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dabigatran etexilate (DE), a direct oral thrombin inhibitor, has been evaluated in children with venous thromboembolism (VTE) using oral solution, pellets, or capsules. OBJECTIVES: This study evaluated DE pharmacokinetics (PK) in children with VTE and the appropriateness of a DE pediatric age- and weight-based dosing algorithm. PATIENTS/METHODS: A population PK model was fitted to data from four single-arm and one randomized, comparative pediatric VTE studies (358 children aged birth to <18 years; 2748 PK observations) and one healthy-adult study (32 males aged <40 years; 1523 PK observations) using nonlinear mixed-effects modeling. A stepwise, covariate, model-building procedure evaluated the influence of covariates (e.g., age, body weight, body surface area [BSA]-normalized renal function, and sex). The final model was used to evaluate the pediatric dosing algorithm, with simulations comparing pediatric trough exposure with reference exposure defined for the pediatric studies. RESULTS: The population PK of dabigatran was adequately described by a two-compartment model with first-order elimination and absorption. Age, weight, BSA-normalized renal function, and sex were statistically significant covariates (all P < .05). Apparent clearance increased with age (independently of body weight), diminished with decreasing BSA-normalized renal function, and was lower in females than males. All disposition parameters increased with body weight escalation (allometric scaling). Simulations confirmed that for all DE formulations, the final pediatric dosing algorithms achieved reference exposure without dose adjustment. CONCLUSIONS: Using a population PK model of DE for children with VTE, simulations showed that the final dosing algorithms were appropriate for all DE formulations; no dose titration was needed.
引用
- Röshammar D, Huang F, Albisetti M, et al. Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. J Thromb Haemost. 2021. PMID: 33636042. doi:10.1111/jth.15277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。